Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial-Reference-Cited by-同舟云学术

Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial

Published:2019-12 Issue:12 Volume:6 Page:e616-e629
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Jackson Graham H,Davies Faith E,Pawlyn Charlotte,Cairns David A,Striha Alina,Collett Corinne,Waterhouse Anna,Jones John R,Kishore Bhuvan,Garg Mamta,Williams Cathy D,Karunanithi Kamaraj,Lindsay Jindriska,Wilson Jamie N,Jenner Matthew W,Cook Gordon,Kaiser Martin F,Drayson Mark T,Owen Roger G,Russell Nigel H,Gregory Walter M,Morgan Gareth J

Publisher

Elsevier BV

Subject

Hematology

Reference26 articles.

1. Evolutionary biology of high-risk multiple myeloma;Pawlyn;Nat Rev Cancer,2017

2. The genetic architecture of multiple myeloma;Morgan;Nat Rev Cancer,2012

3. Depth of response in multiple myeloma: a pooled analysis of three PETHEMA/GEM clinical trials;Lahuerta;J Clin Oncol,2017

4. New criteria for response assessment: role of minimal residual disease in multiple myeloma;Paiva;Blood,2015

5. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX study;Rawstron;J Clin Oncol,2013

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tandem Autologous Stem Cell Transplantation Does Not Benefit High-Risk Myeloma Patients in the Maintenance Era: Real-World Results from The Canadian Myeloma Research Group Database;Transplantation and Cellular Therapy;2024-09

2. Optimizing Autologous Stem Cell Transplantation in Multiple Myeloma: The Impact of Intensive Chemomobilization;Transplantation and Cellular Therapy;2024-08

3. Patient-Reported Outcomes in Phase 3 Clinical Trials for Blood Cancers: A Systematic Review;JAMA Network Open;2024-06-03

4. Alterations in chromosome 1q in multiple myeloma randomized clinical trials: a systematic review;Blood Cancer Journal;2024-01-25

5. Efficacy of Autologous Stem Cell Transplantation for Myeloma Patients with Suboptimal Response: A Multicenter Retrospective Analysis;Transplantation and Cellular Therapy;2023-11